Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, ...
In an interview, Danielle Mitchell of BWICR discussed the importance of increasing diversity in clinical research and making ...
Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...
Stuart Therapeutics completed a Phase 3 trial for ST-100, a treatment for dry eye disease, involving a randomized, ...
The Phase II trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, has reached its enrolment ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival (“DFS”) expected in H1 2025; positive results could support rapid advancement into Phase 3 ...
GATC West Virginia played a role in a groundbreaking AI-powered analysis of a new liver cancer drug in development — an analysis that saved inestimable hours and dollars for the client. GATC West ...
Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.
Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback